BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO
Fund
BHSRX
Price as of:
$58.55
- $0.99
- 1.66%
Primary Theme
fund company
Name
As of 06/02/2026Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-5.6%
1 yr return
12.5%
3 Yr Avg Return
5.4%
5 Yr Avg Return
3.4%
Net Assets
$5.85 B
Holdings in Top 10
46.9%
52 WEEK LOW AND HIGH
$59.5
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 1.45%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 19.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$100
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 06/02/2026Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
BHSRX - Profile
Distributions
- YTD Total Return -5.6%
- 3 Yr Annualized Total Return 5.4%
- 5 Yr Annualized Total Return 3.4%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.37%
- Dividend Yield 4.8%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameBLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO
-
Fund Family NameBlackRock-advised Funds
-
Inception DateSep 12, 2011
-
Shares OutstandingN/A
-
Share ClassR
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerErin Xie
Fund Description
Under normal market conditions, the Fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. Investments in derivatives are counted toward the Fund’s 80% policy to the extent that they provide investment exposure to the securities included within that policy or to one of more market risk factors associated with such securities. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. Health sciences and related industries can include, but are not limited to, businesses involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services, companies engaged in biotechnology and medical research and development, companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment, and companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support. The Fund will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.
The Fund reserves the right to invest up to 20% of its total assets in other types of securities. These may include stocks of companies not associated with health sciences.
BHSRX - Performance
Return Ranking - Trailing
| Period | BHSRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -5.6% | -22.9% | 20.0% | 58.13% |
| 1 Yr | 12.5% | -20.4% | 134.5% | 58.75% |
| 3 Yr | 5.4%* | -6.3% | 23.9% | 44.38% |
| 5 Yr | 3.4%* | -15.5% | 12.3% | 49.03% |
| 10 Yr | 8.8%* | 3.0% | 13.1% | 34.65% |
* Annualized
Return Ranking - Calendar
| Period | BHSRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2025 | 3.0% | -21.9% | 61.0% | 86.88% |
| 2024 | -5.0% | -28.2% | 19.2% | 71.25% |
| 2023 | -0.6% | -8.6% | 19.0% | 71.88% |
| 2022 | -13.1% | -53.9% | 3.2% | 56.77% |
| 2021 | 1.8% | -39.6% | 24.2% | 42.58% |
Total Return Ranking - Trailing
| Period | BHSRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -5.6% | -22.9% | 20.0% | 58.13% |
| 1 Yr | 12.5% | -20.4% | 134.5% | 58.75% |
| 3 Yr | 5.4%* | -6.3% | 23.9% | 44.38% |
| 5 Yr | 3.4%* | -15.5% | 12.3% | 49.03% |
| 10 Yr | 8.8%* | 3.0% | 13.1% | 34.65% |
* Annualized
Total Return Ranking - Calendar
| Period | BHSRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2025 | 15.6% | -0.5% | 63.7% | 62.50% |
| 2024 | 3.5% | -28.2% | 19.2% | 44.38% |
| 2023 | 3.2% | -8.6% | 19.0% | 69.38% |
| 2022 | -6.3% | -53.9% | 3.7% | 29.68% |
| 2021 | 11.4% | -33.9% | 26.0% | 40.00% |
NAV & Total Return History
BHSRX - Holdings
Concentration Analysis
| BHSRX | Category Low | Category High | BHSRX % Rank | |
|---|---|---|---|---|
| Net Assets | 5.85 B | 6.38 M | 37.9 B | 9.38% |
| Number of Holdings | 165 | 24 | 416 | 13.75% |
| Net Assets in Top 10 | 3.06 B | 3.49 M | 22.8 B | 8.75% |
| Weighting of Top 10 | 46.92% | 16.2% | 79.4% | 43.75% |
Top 10 Holdings
- Eli Lilly Co. COM 11.34%
- Johnson Johnson COM 10.22%
- AbbVie Inc. COM 4.11%
- Gilead Sciences Inc. COM 3.96%
- Merck Co., Inc COM 3.55%
- Amgen Inc. COM 3.49%
- UnitedHealth Group Inc. COM 3.04%
- Intuitive Surgical Inc. COM NEW 2.46%
- Abbott Laboratories COM 2.43%
- Danaher Corporation COM 2.31%
Asset Allocation
| Weighting | Return Low | Return High | BHSRX % Rank | |
|---|---|---|---|---|
| Stocks | 98.18% | 88.27% | 106.13% | 53.75% |
| Cash | 1.40% | 0.00% | 32.31% | 50.00% |
| Preferred Stocks | 1.09% | 0.00% | 7.86% | 26.88% |
| Other | 0.00% | -22.99% | 4.13% | 33.75% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 98.71% |
| Bonds | 0.00% | 0.00% | 12.39% | 99.38% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | BHSRX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.96% | 59.26% | 100.00% | 79.35% |
| Basic Materials | 0.73% | 0.00% | 7.16% | 19.35% |
| Financial Services | 0.31% | 0.00% | 1.60% | 9.03% |
| Utilities | 0.00% | 0.00% | 0.00% | 98.71% |
| Technology | 0.00% | 0.00% | 22.69% | 98.71% |
| Real Estate | 0.00% | 0.00% | 5.89% | 99.35% |
| Industrials | 0.00% | 0.00% | 7.02% | 98.71% |
| Energy | 0.00% | 0.00% | 0.00% | 98.71% |
| Communication Services | 0.00% | 0.00% | 9.11% | 98.71% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 98.71% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 99.35% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | BHSRX % Rank | |
|---|---|---|---|---|
| US | 95.71% | 60.50% | 104.41% | 40.00% |
| Non US | 2.48% | 0.00% | 36.86% | 56.25% |
BHSRX - Expenses
Operational Fees
| BHSRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.45% | 0.08% | 4.69% | 33.13% |
| Management Fee | 0.67% | 0.03% | 1.25% | 50.63% |
| 12b-1 Fee | 0.50% | 0.00% | 1.00% | 72.00% |
| Administrative Fee | 0.07% | 0.03% | 0.25% | 25.00% |
Sales Fees
| BHSRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| BHSRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| BHSRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 19.00% | 1.00% | 238.00% | 16.67% |
BHSRX - Distributions
Dividend Yield Analysis
| BHSRX | Category Low | Category High | BHSRX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 4.85% | 0.00% | 6.24% | 98.75% |
Dividend Distribution Analysis
| BHSRX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | Annual | Annual |
Net Income Ratio Analysis
| BHSRX | Category Low | Category High | BHSRX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.37% | -2.54% | 1.85% | 63.40% |
Capital Gain Distribution Analysis
| BHSRX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 09, 2025 | $0.069 | OrdinaryDividend |
| Dec 09, 2025 | $2.856 | CapitalGainLongTerm |
| Dec 09, 2025 | $2.924 | OrdinaryDividend |
| Jul 17, 2025 | $3.837 | CapitalGainLongTerm |
| Dec 11, 2024 | $0.012 | OrdinaryDividend |
| Dec 11, 2024 | $3.092 | CapitalGainLongTerm |
| Dec 11, 2024 | $3.104 | OrdinaryDividend |
| Jul 18, 2024 | $2.491 | CapitalGainLongTerm |
| Dec 07, 2023 | $1.000 | CapitalGainLongTerm |
| Jul 20, 2023 | $1.342 | CapitalGainLongTerm |
| Dec 08, 2022 | $0.022 | OrdinaryDividend |
| Jul 14, 2022 | $4.659 | CapitalGainLongTerm |
| Dec 07, 2021 | $4.143 | OrdinaryDividend |
| Jul 15, 2021 | $2.468 | OrdinaryDividend |
| Dec 07, 2020 | $2.990 | OrdinaryDividend |
| Dec 05, 2019 | $0.018 | CapitalGainShortTerm |
| Dec 05, 2019 | $2.297 | CapitalGainLongTerm |
| Dec 05, 2019 | $0.051 | OrdinaryDividend |
| Dec 06, 2018 | $0.275 | CapitalGainShortTerm |
| Dec 06, 2018 | $4.147 | CapitalGainLongTerm |
| Dec 04, 2017 | $1.894 | CapitalGainLongTerm |
| Dec 06, 2016 | $1.081 | CapitalGainLongTerm |
| Dec 12, 2014 | $1.652 | CapitalGainShortTerm |
| Dec 12, 2014 | $1.713 | CapitalGainLongTerm |
| Dec 13, 2013 | $2.385 | CapitalGainShortTerm |
| Dec 13, 2013 | $1.648 | CapitalGainLongTerm |
| Dec 12, 2012 | $0.745 | CapitalGainShortTerm |
| Dec 12, 2012 | $1.478 | CapitalGainLongTerm |
| Dec 12, 2012 | $0.025 | OrdinaryDividend |
| Dec 08, 2011 | $0.261 | CapitalGainShortTerm |
| Dec 08, 2011 | $1.256 | CapitalGainLongTerm |
BHSRX - Fund Manager Analysis
Managers
Erin Xie
Start Date
Tenure
Tenure Rank
Jul 31, 2003
18.85
18.9%
Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.
Xiang Liu
Start Date
Tenure
Tenure Rank
Jun 01, 2020
2.0
2.0%
Director of BlackRock since 2016. Prior to joining BlackRock in 2008, Mr. Liu was a Partner and Biotech Analyst at Mehta Partners. Mr. Liu began his investment career in 2000 and has a BS from the University of Science & Technology (China), an MBA from the University of Chicago and a PhD degree in Chemistry from Yale University.
Jeff Lee
Start Date
Tenure
Tenure Rank
Jun 01, 2020
2.0
2.0%
Director of BlackRock since 2011. Mr. Lee began his investment career in 2006 and has a BA from Princeton University
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 8.08 | 0.25 |